Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug 23;7(34):55181-55190.
doi: 10.18632/oncotarget.10473.

Serum neuron-specific enolase levels are upregulated in patients with acute lymphoblastic leukemia and are predictive of prognosis

Cheng-Cheng Liu  1   2   3 , Hua Wang  1   2   3 , Jing-Hua Wang  1   2   3 , Liang Wang  1   2   3 , Qi-Rong Geng  1   2   3 , Xiao-Qin Chen  1   2   3 , Yue Lu  1   2   3
Affiliations

Serum neuron-specific enolase levels are upregulated in patients with acute lymphoblastic leukemia and are predictive of prognosis

Cheng-Cheng Liu et al. Oncotarget. .

Abstract

We explored the relationship between neuron-specific enolase (NSE) levels and the clinical features of acute lymphoblastic leukemia (ALL). Seventy ALL patients and forty-two healthy controls were enrolled in this study, and their serum NSE levels were measured using an electrochemiluminescence assay. The serum NSE concentration was higher in ALL patients than in healthy controls. In ALL patients, the mean serum NSE level declined after complete remission (CR) but increased with relapse. In addition, the mean serum NSE level was lower in the CR group than in the non-CR group. High NSE levels were associated with poorer progression-free and overall survival than low NSE levels. Serum NSE levels closely correlated with several clinical features, including the immunophenotype, risk stratification and serum lactate dehydrogenase levels. Multivariate analysis revealed that high NSE expression was an independent prognostic factor in adult ALL patients. NSE mRNA levels were also higher in ALL cell lines and bone marrow mononuclear cells from ALL patients than in control cells. These results suggested that NSE could be a clinical prognostic factor and a potential therapeutic target in ALL.

Keywords: acute lymphoblastic leukemia; biomarker; neuron-specific enolase; prognostic factor; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors have declared no conflicts of interest.

Figures

Figure 1
Figure 1. Serum NSE levels in acute lymphoblastic leukemia patients and healthy controls
The mean concentration of NSE for 70 acute lymphoblastic leukemia patients was 25.01 ng/mL, significantly higher than that of the 42 healthy controls (7.187 ng/mL, P< 0.0001).
Figure 2
Figure 2. ROC curve analysis of the optimal cutoff point for the serum NSE concentration
The most discriminative cutoff value for NSE was 15.2 ng/mL, with an AUC value of 0.886 (P < 0.001). The sensitivity and specificity were 68.6% and 97.6%, respectively.
Figure 3
Figure 3. Serum NSE levels of patients at the time of diagnosis, CR, and relapse
*P<0.05, compared with CR.
Figure 4
Figure 4. Kaplan-Meier survival analysis for all patients with acute lymphoblastic leukemia
Progression-free survival (PFS) and overall survival (OS) were significantly longer in low-NSE patients (≤15.2ng/mL, A, B.) and standard-risk patients C, D. than in high-NSE and high-risk patients, respectively.
Figure 5
Figure 5. NSE mRNA expression in cell lines and bone marrow cells by real-time PCR analysis
A. The NSE levels were significantly higher in all the ALL cell lines than in normal peripheral blood lymphocytes. *P<0.05, compared with normal peripheral blood lymphocytes. B. The NSE levels were significantly higher in the bone marrow mononuclear cells (BM-MCs) of ALL patients than in healthy controls. *P<0.05, compared with BM-MCs of healthy controls.
See this image and copyright information in PMC

References

    1. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350:1535–1548. - PubMed
    1. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013;381:1943–1955. - PMC - PubMed
    1. Gaynon PS, Angiolillo AL, Carroll WL, Nachman JB, Trigg ME, Sather HN, Hunger SP, Devidas M. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report. Leukemia. 2010;24:285–297. - PMC - PubMed
    1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166–178. - PubMed
    1. Nuver J, van den Belt-Dusebout AW, Gietema JA. Long-term survivors of acute lymphoblastic leukemia. N Engl J Med. 2003;349:1973. 1973. - PubMed

LinkOut - more resources